15 results on '"Andersen KE"'
Search Results
2. Oleyl Alcohol May Be an Overlooked Allergen in Pimecrolimus Cream.
- Author
-
Andersen KE
- Subjects
- Humans, Allergens adverse effects, Tacrolimus adverse effects, Treatment Outcome, Double-Blind Method, Administration, Topical, Dermatitis, Atopic drug therapy, Dermatologic Agents therapeutic use
- Published
- 2023
- Full Text
- View/download PDF
3. An effective patient-supporting intervention for topical treatment of psoriasis is also cost-effective.
- Author
-
Svendsen MT, Andersen KE, Feldman SR, Mejldal A, Möller S, and Kongstad LP
- Subjects
- Humans, Cost-Benefit Analysis, Quality of Life, Psoriasis drug therapy
- Abstract
Background: A randomized controlled trial (RCT) of topical treatment combined with regular patient support provided by dermatological nurses in structured consultations of 20-min duration every fourth week improved psoriasis severity, quality of life and treatment adherence compared with topical treatment combined with standard patient support, which is seeing a dermatologist every third month., Objectives: To examine the economic impact of the patient support from a healthcare-sector perspective in the RCT., Methods: Costs for primary care, secondary healthcare services and costs of prescription medication were compared for the intervention and nonintervention groups over 48 weeks. Health benefits were expressed in terms of quality-adjusted life-years (QALYs) measured by the EuroQoL five-dimension three-level questionnaire. Regression analyses were used to estimate incremental cost and QALYs., Results: The incremental cost was estimated at £462, with an average increase of 0.08 QALYs per patients for participants receiving the intervention compared with those receiving standard care. The incremental cost-effectiveness ratio for patients was £5999/QALY. The intervention had an almost 100% probability of being cost-effective at a willingness-to-pay threshold of £30 000 per QALY., Conclusions: Addressing adherence issues is critical to improving outcomes for patients with psoriasis who use topical treatment. The personal support intervention was effective with an acceptable increase in costs., Competing Interests: Conflicts of interest M.T.S. and K.E.A. received a grant from the LEO Foundation to conduct the trial. S.R.F. is a speaker for AbbVie, Alvotech, Amgen, BMS, Janssen, Lilly, Regeneron, Sanofi and Sun; a consultant for AbbVie, Accordant, Almirall, Alvotech, Arcutis, Arena, Argenx, Biocon, BMS, Boehringer, Dermavant, Forte, Helsin, Janssen, LEO Pharma, Micreos, Mylan, Novartis, Ono, Pfizer, Samsung, Sanofi, Sun, UCB, vTv and Voluntis; conducts research for AbbVie, Almirall, BMS, Galderma, Janssen, Lilly, Novartis, Pfizer and UCB; and holds stocks in Sensal Health. The other authors declare no conflicts of interest., (© The Author(s) 2023. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
4. Patients with positive patch test to formaldehyde can be safely vaccinated with formaldehyde-containing vaccines.
- Author
-
Bindslev-Jensen U, Mortz CG, Andersen KE, and Bindslev-Jensen C
- Subjects
- Humans, Patch Tests, Retrospective Studies, Prospective Studies, Formaldehyde adverse effects, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact etiology, Dermatitis, Allergic Contact epidemiology, Vaccines
- Abstract
Background: Prophylactic vaccination against influenza and other epidemic viruses is recommended for citizens above 65 years. Several vaccines may contain traces of formaldehyde and are contra-indicated in patients hypersensitive (in the broadest possible meaning) to formaldehyde. Thorough knowledge on the various subtypes of hypersensitivity is sparse among non-dermatologists and non-allergists, and therefore many patients are prevented from vaccination based on a positive patch test to formaldehyde. The purpose of this retrospective study was to investigate whether patients with positive patch test to formaldehyde subsequently receiving a formaldehyde-containing vaccine and developed a severe adverse reaction., Methods/materials: From January 2000 to June 2021, 169 patients (>50 years) had a positive formaldehyde patch test at the Department of Dermatology and Allergy Center, Odense University Hospital and were included into this retrospective study. The electronic medical record was assessed for receipt of a formaldehyde-containing vaccine after patch test and for subsequent contact with the Acute Ward in the Region of Southern Denmark within 14 days after vaccination., Results: Of the 158 patients residing in the Region of Southern Denmark, 130 patients were vaccinated with one or more formaldehyde-containing vaccines of whom 123 received an influenza vaccine. No contacts to the acute wards were identified., Discussion: Although prospective studies would be beneficial, patients with positive patch test to formaldehyde can be safely vaccinated with formaldehyde-containing vaccines., (© 2023 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
5. Allergic reactivity for different dilutions of eugenol in repeated open application test and patch testing.
- Author
-
Ofenloch RF, Andersen KE, Foti C, Giménez-Arnau AM, Mowitz M, Salvador JFS, Svedman C, and Bruze M
- Subjects
- Humans, Eugenol adverse effects, Patch Tests, Allergens adverse effects, Dose-Response Relationship, Drug, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact etiology, Perfume adverse effects
- Abstract
Background: Eugenol is a known contact sensitiser included in fragrance mix I., Objective: To assess the allergic reactivity to eugenol in different concentrations using patch test as well as repeated open application test (ROAT)., Methods: Overall 67 subjects from 6 European dermatology clinics participated in the study. The ROAT was performed for 21 days twice a day, applying 3 dilutions of eugenol (2.7%-0.5%) and a control. Before and after the ROAT, patch testing with 17 dilutions of eugenol (2.0%-0.00006%) and controls was performed., Results: Out of the 34 subjects with contact allergy to eugenol, 21 (61.8%) showed a positive patch test before ROAT was performed, the lowest positive concentration was 0.031%. The ROAT was positive in 19 (55.9%) of the 34 subjects, the time until a positive reaction occurred was negatively associated with the concentration of the ROAT solution, as well as with the allergic reactivity of the subjects as defined by patch testing. In the patch test after ROAT, 20 of the 34 test subjects (58.8%) showed a positive reaction. In 13 (38.2%) of the 34 test subjects, the patch test result was not reproduceable, still 4 (31.0%) of these 13 subjects developed a positive ROAT., Conclusion: Eugenol can provoke a positive patch test reaction in a very low dose; besides, this hypersensitivity may persist even if a former positive patch test is not reproduceable., (© 2023 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
6. Analysis of Hexavalent Chromium in Cement Samples From Countries Within and Outside the EU: A Study From the International Contact Dermatitis Research Group.
- Author
-
Lejding T, Persson L, Andersen KE, Bruze M, Derevyanko L, Elsner P, Goh CL, Gonçalo M, Goossens A, Gülgün MA, Isaksson M, Ljubojevic Hadzavdic S, Maibach H, Matsunaga K, Mowitz M, Nixon R, Pailin P, Pratt M, Schuttelaar MA, Sukakul T, Verma K, Zimerson E, Özkaya E, and Svedman C
- Subjects
- Humans, Bone Cements, Chromium adverse effects, Dermatitis, Allergic Contact etiology
- Abstract
Background: Allergic contact dermatitis (ACD) caused by hexavalent chromium (Cr(VI)) is often severe and difficult to treat. The content of Cr(VI) in cement can be reduced by, for example, addition of iron(II) sulfate. Since 2005 the content of Cr(VI) in cement is regulated in the EU Directive 2003/53/EC and must not exceed 2 ppm. Since this regulation came into force, ACD caused by cement has markedly been reduced. Objective: To investigate Cr(VI) and total chromium content in samples of cement from countries within and outside the EU. Methods: The members of the International Contact Dermatitis Research Group (ICDRG) were invited to participate in the study with the aim to collect cement samples from geographically different areas. The content of Cr(VI) in the samples was estimated by the diphenyl carbazide spot test, atomic absorption spectroscopy was used to assess the total chromium content. Results: Forty-five cement samples were analyzed, containing amounts of Cr(VI) from <0.1 to >70 ppm. Twenty-one samples contained >2 ppm Cr(VI), 24 contained less. Four of 17 samples from within the EU contained >2 ppm Cr(VI), that is, higher amounts than stipulated in the EU directive, as compared with 17 samples from countries outside the EU. Conclusion: In countries outside the EU, significantly more cement samples contained >2 ppm Cr(VI).
- Published
- 2023
- Full Text
- View/download PDF
7. Stability Characterization of the Novel Anti-Cancer HM-10/10 HDL-Mimetic Peptide.
- Author
-
Dempsey MP, Andersen KE, Wells BM, Taylor MA, Cashman CL, Conrad LB, Kearney CA, Conklin MB, Via ER, Doe EM, Komirisetty R, Dearborn S, Reddy ST, and Farias-Eisner R
- Subjects
- Humans, Female, Peptides pharmacology, Peptides chemistry, Colon pathology, Neoplasms drug therapy, Neoplasms pathology
- Abstract
Epithelial adenocarcinoma of the ovary and colon are associated with the highest rates of cancer-related deaths in women in the U.S. The literature supports the role of HDL-associated apolipoproteins in the treatment of cancer and other pro-inflammatory diseases. Previously, we developed a novel 20-amino acid mimetic peptide, HM-10/10, which potently inhibits tumor development and growth in colon and ovarian cancer. Here, we report the properties of HM-10/10 relative to its stability in vitro. The results demonstrated that HM-10/10 had the highest half-life in human plasma compared to plasma from other species tested. HM-10/10 demonstrated stability in human plasma and simulated gastric environment, increasing its promise as an oral pharmaceutical. However, under conditions modeling the small intestine, HM-10/10 demonstrated significant degradation, likely due to the peptidases encountered therein. Furthermore, HM-10/10 demonstrated no evidence of time-dependent drug-drug interactions, although it demonstrated CYP450 induction slightly above cutoff. As proteolytic degradation is a common limitation of peptide-based therapeutics, we are pursuing strategies to improve the stability properties of HM-10/10 by extending its bioavailability while retaining its low toxicity profile. HM-10/10 holds promise as a new agent to address the international women's health crisis of epithelial carcinomas of the ovary and colon.
- Published
- 2023
- Full Text
- View/download PDF
8. Occupational contact sensitization to Pelargonium zonale hybrids.
- Author
-
Paulsen E, Andersen KE, and Hvid L
- Subjects
- Humans, Patch Tests, Pelargonium, Dermatitis, Allergic Contact, Dermatitis, Occupational
- Published
- 2023
- Full Text
- View/download PDF
9. Regular support provided by dermatological nurses improves outcomes in patients with psoriasis treated with topical drugs: a randomized controlled trial.
- Author
-
Svendsen MT, Feldman SR, Mejldal A, Möller S, Kongstad LP, and Andersen KE
- Subjects
- Humans, Patient Compliance, Quality of Life, Severity of Illness Index, Treatment Outcome, Dermatologic Agents therapeutic use, Psoriasis drug therapy
- Abstract
Background: Patient adherence to topical antipsoriatic drugs is often poor, leading to poor efficacy. Use of long-term support delivered by dermatological nurses to patients treated with topical drugs may improve outcome., Aim: To evaluate whether regular support from dermatological nurses improves outcome and treatment adherence in patients with psoriasis receiving topical medications., Methods: We conducted a randomized controlled trial (RCT) (clinicaltrials.gov registration NCT04220554), in which patients received once-daily topical medications (containing corticosteroids and/or calcipotriol) for as long as their psoriasis was visible. The patients were randomly allocated to standard care by the dermatologist either with (n = 51) or without (n = 52) support from dermatological nurses. The nurse support intervention consisted of a structured dermatological consultation at baseline and Week 1, followed by contact with a nurse each month (in the outpatient clinic or by telephone). The primary outcome was severity of psoriasis, which was measured by the Lattice System Physician's Global Assessment (LS-PGA) and assessed by intention-to-treat analyses using linear mixed regression models for longitudinal data. Secondary outcomes were quality of life (measured by the Dermatology Life Quality Index; DLQI) and good adherence (defined as use of ≥ 80% of recommended doses)., Results: In total, 92 patients (89%) completed the 48-week trial period. The intervention group improved more than the nonintervention group from baseline to Week 24 in LS-PGA (2.21 vs. 1.28, P = 0.001) and in DLQI at Week 12 (6.50 vs. 1.55, P < 0.001). Differences between the two groups in favour of the intervention were observed throughout the study period. More participants in the intervention group had good adherence compared with the nonintervention group (36% vs. 14%, P < 0.001)., Conclusion: Regular, continued patient support from dermatological nurses increased the efficacy of psoriasis treatment, improved quality of life and enhanced long-term adherence to topical antipsoriatic drugs. However, there is still room for more improvement., (© 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)
- Published
- 2022
- Full Text
- View/download PDF
10. Contact dermatitis in children caused by diabetes devices.
- Author
-
Alves da Silva C, Bregnhøj A, Mowitz M, Bruze M, Andersen KE, and Sommerlund M
- Subjects
- Acrylates adverse effects, Adhesives adverse effects, Adhesives chemistry, Allergens, Benzoyl Peroxide, Blood Glucose, Blood Glucose Self-Monitoring, Camphanes, Child, Humans, Patch Tests adverse effects, Quality of Life, Retrospective Studies, Dermatitis, Allergic Contact etiology, Diabetes Mellitus, Insulins
- Abstract
Background: Insulin pumps and glucose monitoring devices improve diabetes mellitus control and enhance patients' quality of life. However, a growing number of adverse cutaneous reactions related to the use of these devices have been reported., Objective: To investigate the culprits of localized contact dermatitis in paediatric patients with diabetes caused by insulin pumps and glucose monitoring devices., Methods: Retrospective analysis of 15 paediatric patients patch tested as part of a clinical investigation for skin reactions associated with insulin pumps and glucose monitoring devices., Results: Seven patients had positive patch test reactions to isobornyl acrylate (IBOA) and five had positive reactions to benzoyl peroxide (BP). Positive patch test reactions to materials from the glucose sensor and/or insulin pump were seen in 10 of the 15 patients. Three had positive reactions to adhesive remover wipe from Smith and Nephew Remove and four had reactions to EMLA plaster., Conclusion: A high share of patients showed positive reactions to IBOA and/or their medical devices (insulin pumps or glucose devices). A third of patients showed positive reactions to BP. The presence of additional unidentified allergens cannot be excluded, highlighting the importance of access to a full description of the chemical composition of the devices., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
11. Patch Testing With Nickel Sulfate 5.0% Traces Significantly More Contact Allergy Than 2.5%: A Prospective Study Within the International Contact Dermatitis Research Group.
- Author
-
Svedman C, Ale I, Goh CL, Goncalo M, Lee JY, Ljubojevic Hadžavdić S, Matsunaga K, Bach RO, Pratt M, Puangpet P, Sasseville D, Andersen KE, Dahlin J, Suzuki K, Yagami A, and Bruze M
- Subjects
- Humans, Patch Tests, Prospective Studies, Petrolatum, Allergens adverse effects, Nickel adverse effects, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact epidemiology, Dermatitis, Allergic Contact etiology
- Abstract
Background: Nickel allergy is the most common contact allergy, and a nickel salt is, therefore, included in most baseline patch test series. In the baseline series of the International Contact Dermatitis Research Group and the American Contact Dermatitis Society, nickel sulfate hexahydrate (NSH) in petrolatum at 2.5% is included, whereas NSH at 5.0% is included in many other baseline series, such as the European and Swedish ones., Objective: The aim of the study is to investigate whether NSH at 5.0% detects significantly more contact allergy than NSH 2.5% when both preparations are tested simultaneously in consecutive dermatitis patients., Patients and Methods: Two thousand two hundred eighty-seven consecutive dermatitis patients were patch tested simultaneously with NSH in petrolatum at 2.5% and 5.0%. The allergy rates were compared for all clinics individually and combined using McNemar test, 2-sided., Results: Contact allergy to NSH 5.0% and 2.5% was found in 20.3% and 16.8%, respectively ( P < 0.0001). In 6 of 11 clinics, significantly more patients tested positive to the higher NSH concentration. For the 2 clinics in North America combined, significantly more patients tested positive to NSH 5.0%., Conclusions: The NSH preparation in the International Contact Dermatitis Research Group baseline patch test series should be considered to be changed from NSH 2.5% (1 mg NSH/cm 2 ) to 5.0% (2 mg NSH/cm 2 )., Competing Interests: The authors have no funding or conflicts of interest to declare., (Copyright © 2022 American Contact Dermatitis Society. All Rights Reserved.)
- Published
- 2022
- Full Text
- View/download PDF
12. Guidelines for diagnosis, prevention, and treatment of hand eczema.
- Author
-
Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, Bauer A, Brans R, Cannavo A, Christoffers WA, Crépy MN, Elsner P, Fartasch M, Filon FL, Giménez-Arnau AM, Gonçalo M, Guzmán-Perera MG, Hamann CR, Hoetzenecker W, Johansen JD, John SM, Kunkeler ACM, Hadzavdic SL, Molin S, Nixon R, Oosterhaven JAF, Rustemeyer T, Serra-Baldrich E, Shah M, Simon D, Skudlik C, Spiewak R, Valiukevičienė S, Voorberg AN, Weisshaar E, and Agner T
- Subjects
- Humans, Patch Tests, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact prevention & control, Eczema diagnosis, Eczema prevention & control, Hand Dermatoses diagnosis, Hand Dermatoses prevention & control
- Abstract
Background: Hand eczema is a common inflammatory skin disorder. Health care providers need continuously updated information about the management of hand eczema to ensure best treatment for their patients., Objectives: To update the European Society of Contact Dermatitis guideline on the diagnosis, prevention, and treatment on of hand eczema., Method: The Guideline Development Group (GDG) was established on behalf of the ESCD. A call for interest was launched via the ESCD website and via the ESCD members' mailing list. Appraisal of the evidence for therapeutic and preventive interventions was applied and a structured method of developing consensus was used and moderated by an external methodologist. The final guideline was approved by the ESCD executive committee and was in external review on the ESCD webpage for 1 month., Results: Consensus was achieved for several statements and management strategies., Conclusion: The updated guideline should improve management of hand eczema., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
13. The significance of the Lattice-System Physician's Global Assessment as a research tool for measuring mild-to-moderate psoriasis.
- Author
-
Svendsen MT and Andersen KE
- Subjects
- Double-Blind Method, Humans, Severity of Illness Index, Treatment Outcome, Physicians, Psoriasis diagnosis
- Abstract
Competing Interests: Conflicts of interest Drs Svendsen and Andersen have received research funds from LEO Pharma. The views and opinions expressed herein are those of the authors.
- Published
- 2022
- Full Text
- View/download PDF
14. A comparison of patch testing with nickel sulfate in TRUE Test and in petrolatum at 2.5% and 5% concentrations.
- Author
-
Bach RO, Svendsen MT, Mose KF, Bruze M, Svedman C, and Andersen KE
- Subjects
- Dermatitis, Allergic Contact etiology, Humans, Dermatitis, Allergic Contact diagnosis, Nickel administration & dosage, Nickel adverse effects, Patch Tests methods, Petrolatum administration & dosage
- Published
- 2022
- Full Text
- View/download PDF
15. Long-term improvement of psoriasis patients' adherence to topical drugs: testing a patient-supporting intervention delivered by healthcare professionals.
- Author
-
Svendsen MT, Feldman SR, Möller S, Kongstad LP, and Andersen KE
- Subjects
- Adult, Health Personnel, Humans, Patient Compliance, Quality of Life, Pharmaceutical Preparations, Psoriasis diagnosis, Psoriasis drug therapy
- Abstract
Background: Psoriasis affects 2-4% of the Western adult population and is a socio-economic burden for patients and society. Topical drugs are recommended as first-line treatment for mild-to-moderate psoriasis, but low adherence is a barrier to treatment success. Psoriasis patients require support, in order to improve their long-term use of topical drugs. The project aims to test whether a patient-supporting intervention delivered by dermatology nurses can reduce the severity of psoriasis, improve the use of topical drugs, and is cost-effective compared to standard procedure., Methods: The intervention consists of improved support delivered to patients by three experienced dermatology nurses, who will support patients on a regular basis by consultations with a focus on providing reminder systems, accountability, reinforcement, and building trust in the treatment. Each patient will be supported by the same dermatology nurse throughout the entire study period. The effect will be compared with standard procedure. The intervention will be tested in a randomized controlled trial during a 48-week period. A group of patients with moderate-to-severe psoriasis (psoriasis affecting ≥ 4% of the total body surface area) and 18-85 years of age who are prescribed topical treatment will be randomized to a non-intervention (n ≈ 57) or intervention group (n ≈ 57). Participants in both arms will be prescribed topical preparations containing corticosteroid and/or calcipotriol. The primary outcome will be a change in the severity of psoriasis, measured as reduction in the Lattice-System Physician's Global Assessment. Secondary outcomes will include changes in health-related quality of life (measured by disease specific and generic questionnaires), primary adherence (i.e., proportion of filled prescriptions), and secondary adherence by objective measure (rate of topical drug consumption (obtained by weighing medication packages) compared to estimated recommended consumption). A health economic evaluation is planned to run alongside the trial. Participants' total health costs will be estimated on the basis of health costs reported to the national health registries and costs spent on the intervention, after which a cost-utility and cost-effectiveness analysis will be carried out., Discussion: If the intervention can reduce the severity of psoriasis in a significant manner and is economically favorable compared to standard treatment, there is potential for implementing the intervention in dermatology clinics., Trial Registration: Clinicaltrials.gov NCT04220554 . Registered on January 7, 2020. Study results, either positive, negative, or inconclusive, will be published on www.clinicaltrials.gov . Trial registration no. with the Danish Regional Committee on Health Research Ethics, registration no. 72613., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.